The invention pertains to the field of immunotherapy. The present invention provides a new use of anti-CD127 agent, in particular anti-CD127 antibodies or related compounds for the treatment and/or the prevention of cancer.

The invention relates to a method for treating a patient having a CD127-positive cancer, in particular a CD127-positive leukemia, by administering to the patient a therapeutic dose of an anti-CD127 agent, the anti-CD127 agent having the capability to enhance the Antibody Dependent Cellular Phagocytosis (ADCP) activity of macrophages targeting CD127-positive cancer cells, and that does not have Antibody Dependent Cytotoxic Activity (ADCC), in particular on immune cells, more particularly on T cells.

Described herein are compositions and methods for treating cancer and autoimmune diseases.

Provided herein is a cell comprising a recombinant nucleic acid encoding a transmembrane protein that has an extracellular binding domain that specifically binds to a brain-selective extracellular antigen, e.g., MOG, CDH10, PTPRZ1 or NRCAM, wherein the cell does not comprise a nucleic acid encoding an antigen-specific therapeutic that binds to a killing antigen expressed by a glioblastoma.

The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.

The present invention relates to an immunogenic conjugate comprising: a carrier protein and at least one polypeptide having at most 100 amino acids comprising a sequence of 5 to 50 amino acids of interleukin 6 (IL-6) or IL-6 receptor (IL-6R), or a variant sequence having at least 75% identity with the sequence of 5 to 50 amino acids of IL-6 or IL-6R, wherein the polypeptide is covalently linked to the carrier protein and the carrier protein is a non-toxic mutant diphtheria toxin.

The present disclosure relates to a composition capable of diagnosing cancer, specifically pancreatic cancer or the like, a diagnostic kit comprising the same, and a method of providing information for diagnosis using the composition. Also, the present disclosure relates to a pharmaceutical composition capable of preventing or treating pancreatic cancer.

The present invention relates to antigen-based immunotherapy targeting interleukin 13 receptor alpha 2 (IL13RA2), BIRC5 and/or FOXM1 for treatment of adrenal cancers. In particular, the present invention provides the use of a (poly)peptide comprising an epitope of IL13RA2, BIRC5 and/or FOXM1 or a sequence variant thereof for treatment of an adrenal cancer. Moreover, the present invention also provides combinations of the (poly)peptide comprising an epitope of IL13RA2, BIRC5 and/or FOXM1 or a sequence variant thereof with (poly)peptides comprising other epitopes or sequence variants thereof for treatment of adrenal cancers.

Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.

Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.

The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with reduced Tet, e.g., Tet2 function or expression, and methods of use therefore. The invention further provides Tet2 inhibitors and methods of use therefore in connection with CAR T cells.